Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.60 |
| ▸ | GBA1 | P04062 | 1/20 | 0.59 |
| ▸ | KIT | P10721 | 1/20 | 0.59 |
| ▸ | CKS1B | P61024 | 2/20 | 0.54 |
| ▸ | SKP1 | P63208 | 2/20 | 0.54 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL942427 | 0.85 | GPR119 (0.64) | GPR119GBA1KITCKS1BSKP1 | |
| Hydrochloric Acid SCHEMBL6812121 | 0.84 | GPR119 (0.63) | GPR119GBA1KITCKS1BSKP1 | |
| SCHEMBL3775474 | 0.81 | GPR119 (0.58) | GPR119GBA1KITMAPT | |
| SCHEMBL391852 | 0.81 | GBA1 (0.57) | GPR119GBA1KITCKS1BSKP1 | |
| SCHEMBL6645424 | 0.81 | GPR119 (0.57) | GPR119CKS1BSKP1SKP2MAPT | |
| SCHEMBL20293614 | 0.81 | GPR119 (0.68) | GPR119CKS1BSKP1SKP2MAPT | |
| SCHEMBL6644278 | 0.81 | GPR119 (0.68) | GPR119CKS1BSKP1SKP2MAPT | |
| SCHEMBL12964579 | 0.81 | GPR119 (0.77) | GPR119CKS1BSKP1SKP2MAPT | |
| SCHEMBL22371659 | 0.81 | GPR119 (0.61) | GPR119CKS1BSKP1SKP2MAPT | |
| SCHEMBL594813 | 0.80 | GPR119 (0.80) | GPR119GBA1KITCKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266764-A1 | Hydroxamic acid derivatives | HANNAH DUNCAN ROBERT | 2004-12-30 | — | — | US | disclosed |
| US-6809100-B2 | 2-(4-(4-FURAN-2-YLPHENYL)PIPERAZINE-1-SULFONYLMETHYL)-N-HYDROXY -3-METHYLBUTYRAMIDE, FOR EXAMPLE; TREATMENT OF CANCER, INFLAMMATION, OR AN AUTOIMMUNE, INFECTIOUS OR OCULAR DISEASE | DARWIN DISCOVERY LTD. (GB) | 2004-10-26 | — | — | US | disclosed |
| US-6787536-B2 | A HYDROXAMIC ACID COMPOUND CONTAINING HETEROAROMATIC RING ATTACHED TO SULFONYL GROUP THROUGH NITROGEN ATOM, INHIBITOR OF MATRIX METALLOPRETEINASE, USEFUL FOR TREATING DEGENERATIVE DISEASES AND CERTAIN CANCER | DARWIN DISCOVERY LIMITED (GB) | 2004-09-07 | — | — | US | disclosed |
| US-20030216404-A1 | Hydroxamic acid derivatives | HANNAH DUNCAN ROBERT (GB) | 2003-11-20 | — | — | US | disclosed |
| EP-1282614-B1 | HYDROXAMIC ACID DERIVATIVES | DARWIN DISCOVERY LTD (GB) | 2003-11-12 | — | — | EP | disclosed |
| EP-1282614-A1 | HYDROXAMIC ACID DERIVATIVES | Darwin Discovery Limited (GB) | 2003-02-12 | — | — | EP | disclosed |
| US-20020037900-A1 | Hydroxamic acid derivatives | DARWIN DISCOVERY LIMITED (GB) | 2002-03-28 | — | — | US | disclosed |
| WO-2001087870-A1 | HYDROXAMIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037900-A1 | Hydroxamic acid derivatives | ADAM17, ADAM10, ADAM33 | GPR119 4313/4885GBA1 354/4885KIT 2965/4885 |
| US-20030216404-A1 | Hydroxamic acid derivatives | ADAM17, ADAM10, ADAM33 | GPR119 4313/4885GBA1 354/4885KIT 2965/4885 |
| US-20040266764-A1 | Hydroxamic acid derivatives | ADAM17, ADAM10, ADAM33 | GPR119 4313/4885GBA1 354/4885KIT 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.